Biolegend, 124301, Purified anti-mouse CD274 (B7-H1, PD-L1) Antibody, 50μg

CD274, also known as B7-H1 or programmed death ligand 1 (PD-L1), is a 40 kD type I transmembrane protein and a member of the B7 family within the immunoglobulin receptor superfamily. It is expressed on T cells, B cells, NK cells, dendritic cells, IFN-γ activated endothelial cells, and monocytes. B7-H1 is one of the ligands of PD-1. The interaction of B7-H1 with PD-1 plays an important role in the inhibition of T cell responses. Other studies have shown that B7-H1 is able to costimulate T cell growth and cytokine production. CD274 is involved in costimulation essential for T cell proliferation and production of IL-10 and IFN-γ, in an IL-2-dependent and a PD-1-independent manner. Its interaction with PD-1 inhibits T cell proliferation and cytokine production.
50μg
Verified Reactivity: Mouse
Antibody Type: Monoclonal
Host Species: Rat
Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation: The antibody was purified by affinity chromatography.
Concentration: 0.5 mg/mL
Storage & Handling: The antibody solution should be stored undiluted between 2°C and 8°C.
Application: FC - Quality tested IHC-F - Verified Block - Reported in the literature, not verified in house
Recommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 1.0 µg per million cells in 100 µL volume. It is recommended that the reagent be titrated for optimal performance for each application.
Application Notes: Additional reported applications (for the relevant formats) include: immunofluorescence4, blocking6,7,8,9, and immunohistochemistry of acetone-fixed frozen sections4, 11. The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 124303). For highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 124318) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin <0.01 EU/µg).
Application References(PubMed link indicates BioLegend citation): Maier H, et al. 2007. J. Immunol. 178:2714. Meng Q, et al. 2006. Invest. Ophthalmol. Vis. Sci. 47:4444. PubMed Scarlett UK, et al. 2012. J Exp Med. 209:495. PubMed Grabie N, et al. 2007. Circulation 116:2062. (IF, IHC) Paterson AM, et al. 2011. J. Immunol. 187:1097. Channappanavar R, et al. 2012. PLoS One 7:e39757. (Block) Schreiber HA, et al. 2010. PLoS One 5:e11453. (Block) PubMed Muthumani K, et al. 2011. J. Immunol. 187:2932. (Block) PubMed Cripps JG, et al. 2010. Hepatology 52:1350. (Block) PubMed Murakami R, et al. 2013. PLoS One. 8:73270. PubMed Riella LV, et al. 2011. Am. J. Transplant 11:832-40. (IHC) Lei GS, et al. 2015. Infect Immun. 83:572. PubMed
Product Citations: Sun Y, et al. 2022. Mol Ther Oncolytics. 26:105. PubMed Peymanfar Y, et al. 2023. Int J Mol Sci. 24:. PubMed Hutton C, et al. 2021. Cancer Cell. 39:1227. PubMed Liu CJ, et al. 2020. Neuro Oncol. 22:1276. PubMed Li H, et al. 2022. Cancer Cell. 40:36. PubMed Moore AR, et al. 2022. Cell Rep. 41:111651. PubMed Xiong W, et al. 2022. Nat Commun. 13:1700. PubMed Dieterich LC, et al. 2017. Front Immunol. 0.379166667. PubMed Iwai T, et al. 2021. Mol Cancer Ther. 20:2519. PubMed Muhammad F, et al. 2020. Front Immunol. 975:11. PubMed Herold M, et al. 2015. J Immunol. 195: 3584 - 3595. PubMed Wang G, et al. 2020. Nat Commun. 11:1395. PubMed Schofield DJ, et al. 2021. MAbs. 13:1857100. PubMed Tan Z, et al. 2020. Mol Ther Oncolytics. 16:302. PubMed Huang B, et al. 2015. PLoS One. 10: 0134715. PubMed Lei G, et al. 2015. Infect Immun . 83:572. PubMed Singh M, et al. 2017. Nat Commun. 8:1447. PubMed Hoves S, et al. 2018. J Exp Med. 215:859. PubMed Meng Q, et al. 2006. Invest Ophthalmol Vis Sci. 47:4444. PubMed Murakami R, et al. 2013. PLoS One. 8:73270. PubMed Yahata T, et al. 2019. Cancer Sci. 110:1279. PubMed Tanaka Y, et al. 2020. Sci Rep. 10:17284. PubMed Kong F, et al. 2021. Front Immunol. 12:670646. PubMed Speranza MC, et al. 2018. Neuro Oncol. 20:225. PubMed Muhammad F, et al. 2020. J Autoimmun. 111:102441. PubMed Scarlett U, et al. 2012. J Exp Med. 209:425. PubMed Sano Y, et al. 2021. Mol Cancer Res. 19:507. PubMed Zhao T, et al. 2022. JCI Insight. 7:. PubMed Mao W, et al. 2019. J Immunother Cancer. 0.484027778. PubMed Roussey JA, et al. 2017. J Immunol. 199:3535. PubMed Jiao S, et al. 2020. Cell. 179(5):1177-1190.e13.. PubMed Lin A, et al. 2022. Bioeng Transl Med. 7:e10314. PubMed Bassi &, et al. 2012. Diabetes. 61:2534. PubMed Iida Y, et al. 2020. J Immunother Cancer. 8:. PubMed Li Z, et al. 2022. Transl Cancer Res. 11:3698. PubMed Hirose T, et al. 2017. PLoS One. 12(6):e0178765. PubMed Knier B, et al. 2018. Nat Immunol. 1.722916667. PubMed Giles DA, et al. 2018. J Clin Invest. 128:5322. PubMed Mitchell LA, et al. 2019. Oncotarget. 10:2252. PubMed
RRID: AB_961226 (BioLegend Cat. No. 124301) AB_961228 (BioLegend Cat. No. 124302)
Structure: 40 kD type I transmembrane protein member of B7 family within the immunoglobulin receptor superfamily
Distribution: T cells, B cells, NK cells, dendritic cells, IFN-γ activated endothelial cells, and monocytes
Ligand/Receptor: PD-1 (PDCD1)
Cell Type: B cells, Dendritic cells, Endothelial cells, Monocytes, NK cells, T cells
Biology Area: Cancer Biomarkers, Costimulatory Molecules, Immunology
Molecular Family: Adhesion Molecules, CD Molecules, Immune Checkpoint Receptors
Antigen References: 1. Sharpe A, et al. 2007. Nat. Immunol. 8:239. 2. Dong H, et al. 1999. Nat. Med. 5:1365. 3. Freeman G, et al. 2000. J. Exp. Med. 192:1027.
Gene ID: 60533
UniProt: View information about CD274 on UniProt.org
Clone: 10F.9G2
Regulatory Status: RUO
Other Names: B7-H1, PD-L1
Isotype: Rat IgG2b, κ